Regulation of intraocular pressure in mice: Structural analysis of dopaminergic and serotonergic systems in response to cabergoline

Biochemical Pharmacology

Volumn 86, Issue 9, 2013, Pages 1347-1356

  Platania, Chiara Bianca Maria ^a   Leggio, Gian Marco ^a   Drago, Filippo ^a   Salomone, Salvatore ^a   Bucolo, Claudio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Dopaminergic system; GPCR; Intraocular pressure; Molecular modeling; Optic neuropathy; Serotonergic system

Indexed keywords

CABERGOLINE; DOPAMINE 3 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; IN VIVO STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; MALE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRESSURE MEASUREMENT; PRIORITY JOURNAL; REGULATORY MECHANISM; SEROTONINERGIC SYSTEM; TOPICAL TREATMENT;

DOPAMINERGIC SYSTEM; GPCR; INTRAOCULAR PRESSURE; MOLECULAR MODELING; OPTIC NEUROPATHY; SEROTONERGIC SYSTEM;

ANIMALS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOLINES; HUMANS; INTRAOCULAR PRESSURE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; OCULAR HYPERTENSION; PROTEIN CONFORMATION; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTORS, DOPAMINE D3; SEQUENCE ALIGNMENT;

EID: 84886798362     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.08.010     Document Type: Article

References (45)

1. B. Nemesure, R. Honkanen, A. Hennis, S.Y. Wu, and M.C. Leske Incident open-angle glaucoma and intraocular pressure Ophthalmology 114 2007 1810 1815
2. C. Bucolo, S. Salomone, F. Drago, M. Reibaldi, A. Longo, and M.G. Uva Pharmacological management of ocular hypertension: current approaches and future prospective Curr Opin Pharmacol 13 2013 50 55
3. N.A. Sharif, M.A. McLaughlin, C.R. Kelly, P. Katoli, C. Drace, and S. Husain Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes Exp Eye Res 88 2009 386 397
4. J.W. Kiel, and H.A. Reitsamer Paradoxical effect of phentolamine on aqueous flow in the rabbit J Ocul Pharmacol Ther 23 2007 21 26
5. C. Bucolo, G.M. Leggio, A. Maltese, A. Castorina, V. D'Agata, and F. Drago Dopamine-(3) receptor modulates intraocular pressure: implications for glaucoma Biochem Pharmacol 83 2012 680 686
6. M.J. Millan, L. Maiofiss, D. Cussac, V. Audinot, J.A. Boutin, and A. Newman-Tancredi Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes J Pharmacol Exp Ther 303 2002 791 804
7. A. Newman-Tancredi, D. Cussac, V. Audinot, J.P. Nicolas, F. De Ceuninck, and J.A. Boutin Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor J Pharmacol Exp Ther 303 2002 805 814
8. C.B. Platania, S. Salomone, G.M. Leggio, F. Drago, and C. Bucolo Homology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluation PLoS ONE 7 2012 e44316
9. D. Accili, C.S. Fishburn, J. Drago, H. Steiner, J.E. Lachowicz, and B.H. Park A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice Proc Natl Acad Sci USA 93 1996 1945 1949
10. C. Bucolo, and F. Drago Carbon monoxide and the eye: implications for glaucoma therapy Pharmacol Ther 130 2011 191 201
11. M. Goujon, H. McWilliam, W. Li, F. Valentin, S. Squizzato, and J. Paern A new bioinformatics analysis tools framework at EMBL-EBI Nucleic Acids Res 38 2010 W695 W699
12. A.M. Waterhouse, J.B. Procter, D.M. Martin, M. Clamp, and G.J. Barton Jalview Version 2-a multiple sequence alignment editor and analysis workbench Bioinformatics 25 2009 1189 1191
13. J. Zhang, and Y. Zhang GPCRRD: G protein-coupled receptor spatial restraint database for 3D structure modeling and function annotation Bioinformatics 26 2010 3004 3005
14. W. Humphrey, A. Dalke, and K. Schulten VMD: visual molecular dynamics J Mol Graph 14 1996 33 38 27-8
15. J.C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, and E. Villa Scalable molecular dynamics with NAMD J Comput Chem 26 2005 1781 1802
16. R. Huey, G.M. Morris, A.J. Olson, and D.S. Goodsell A semiempirical free energy force field with charge-based desolvation J Comput Chem 28 2007 1145 1152
17. G. Neudert, and G. Klebe DSX: a knowledge-based scoring function for the assessment of protein-ligand complexes J Chem Inf Model 51 2011 2731 2745
18. V. Audinot, A. Newman-Tancredi, A. Gobert, J.M. Rivet, M. Brocco, and F. Lejeune A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194 J Pharmacol Exp Ther 287 1998 187 197
19. S. Kortagere, S.Y. Cheng, T. Antonio, J. Zhen, M.E. Reith, and A.K. Dutta Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies Biochem Pharmacol 81 2011 157 163
20. D. Wacker, C. Wang, V. Katritch, G.W. Han, X.P. Huang, and E. Vardy Structural features for functional selectivity at serotonin receptors Science 340 2013 615 619
21. C. Wang, Y. Jiang, J. Ma, H. Wu, D. Wacker, and V. Katritch Structural basis for molecular recognition at serotonin receptors Science 340 2013 610 614
22. A.R. Knight, A. Misra, K. Quirk, K. Benwell, D. Revell, and G. Kennett Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors Naunyn Schmiedebergs Arch Pharmacol 370 2004 114 123
23. N.A. Sharif, and M. Senchyna Serotonin receptor subtype mRNA expression in human ocular tissues, determined by RT-PCR Mol Vis 12 2006 1040 1047
24. 2A) receptors: role in IOP reduction Invest Ophthalmol Vis Sci 47 2006 4001 4010
25. J.M. Beaulieu, and R.R. Gainetdinov The physiology, signaling, and pharmacology of dopamine receptors Pharmacol Rev 63 2011 182 217
26. D.E. Potter, and D.J. Shumate Cianergoline lowers intraocular pressure in rabbits and monkeys and inhibits contraction of the cat nictitans by suppressing sympathetic neuronal function J Ocul Pharmacol 3 1987 309 321
27. Q.A. Mekki, S.M. Hassan, and P. Turner Bromocriptine lowers intraocular pressure without affecting blood pressure Lancet 1 1983 1250 1251
28. D.E. Potter, and J.A. Burke Effects of ergoline derivatives on intraocular pressure and iris function in rabbits and monkeys Curr Eye Res 2 1982 281 288
29. O. Geyer, D. Robinson, and M. Lazar Hypotensive effect of bromocriptine in glaucomatous eyes J Ocul Pharmacol 3 1987 291 294
30. M. Virno, L. Taverniti, F. De Gregorio, L. Sedran, and F. Longo Increase in aqueous humor production following D1 receptors activation by means of ibopamine Int Ophthalmol 20 1996 141 146
31. J.R. Piltz, R.A. Stone, S. Boike, D.E. Everitt, N.H. Shusterman, and P. Audet Fenoldopam, a selective dopamine-1 receptor agonist, raises intraocular pressure in males with normal intraocular pressure J Ocul Pharmacol Ther 14 1998 203 216
32. J.A. May, M.A. McLaughlin, N.A. Sharif, M.R. Hellberg, and T.R. Dean Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys J Pharmacol Exp Ther 306 2003 301 309
33. N.A. Sharif, C.R. Kelly, J.Y. Crider, and T.L. Davis Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension J Ocul Pharmacol Ther 22 2006 389 401
34. E. Chu, T.C. Chu, and D.E. Potter Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: a dopamine(3) receptor agonist J Pharmacol Exp Ther 293 2000 710 716
35. S.E. Ohia, G.L. Zhan, A.M. Leday, C.A. Opere, K.H. Kulkarni, and L.C. Harris Ocular pharmacology of bicyclic hexahydroaporphines Methods Find Exp Clin Pharmacol 27 2005 87 93
36. S.L. Saha, I.N. Igbo, C.A. Opere, G.L. Zhan, J. Taniyama, and S.E. Ohia Assessment of the intraocular pressure-lowering activity of bicyclic derivatives of 1-substituted benzyloctahydroisoquinoline J Ocul Pharmacol Ther 17 2001 413 420
37. D.E. Potter, M.J. Ogidigben, and T.C. Chu Lisuride acts at multiple sites to induce ocular hypotension and mydriasis Pharmacology 57 1998 249 260
38. M. Ogidigben, T.C. Chu, and D.E. Potter Ocular hypotensive action of a dopaminergic (DA2) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine J Pharmacol Exp Ther 267 1993 822 827
39. G.C. Chiou, and Y.J. Chen Improvement of ocular blood flow with dopamine antagonists on ocular-hypertensive rabbit eyes Zhongguo Yao Li Xue Bao 13 1992 481 484
40. C.E. Crosson, J.A. Burke, M.F. Chan, and D.E. Potter Ocular effects of a N,N-disubstituted 5-OH aminotetralin (N-0437): evidence for a dual mechanism of action Curr Eye Res 6 1987 1319 1326
41. G.C. Chiou, and F.Y. Chiou Dopaminergic involvement in intraocular pressure in the rabbit eye Ophthalmic Res 15 1983 131 135
42. G.C. Chiou, and B.H. Li Ocular hypotensive actions of serotonin antagonist-ketanserin analogs J Ocul Pharmacol 8 1992 11 21
43. S. Salomone, and C. Waeber Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects Front Pharmacol 2 2011 9
44. E.Y. Chien, W. Liu, Q. Zhao, V. Katritch, G.W. Han, and M.A. Hanson Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist Science 330 2010 1091 1095
45. V. Singh, and P. Somvanshi Homology modeling of adenosine A2A receptor and molecular docking for exploration of appropriate potent antagonists for treatment of Parkinson's disease Curr Aging Sci 2 2009 127 134